Accumulating Evidence and Research Organization (AERO) model: A new tool for representing, analyzing, and planning a translational research program

Trials

Volumn 14, Issue 1, 2013, Pages

  Hey, Spencer P ^a   Heilig, Charles M ^b   Weijer, Charles ^c  

^a MCGILL UNIVERSITY   (Canada)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c WESTERN UNIVERSITY   (Canada)

Author keywords

Decision making; Graph theoretic model; Moxifloxacin; Research coordination; Research efficiency; Research planning; Robustness; Translational medicine; Tuberculosis

Indexed keywords

MOXIFLOXACIN;

ARTICLE; DRUG RESISTANT TUBERCULOSIS; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL RESEARCH; NONHUMAN; ORGANIZATION; TRANSLATIONAL RESEARCH;

ANIMALS; ANTITUBERCULAR AGENTS; AZA COMPOUNDS; COMPUTER GRAPHICS; EVIDENCE-BASED MEDICINE; HUMANS; MODELS, ORGANIZATIONAL; ORGANIZATIONAL OBJECTIVES; PHOTIC STIMULATION; QUINOLINES; TIME FACTORS; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME; TUBERCULOSIS; VISUAL PERCEPTION; WORKFLOW;

EID: 84878222780     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-14-159     Document Type: Article

References (34)

1. Tall AR, Yvan-Charvet L, Wang N. The Failure of Torcetrapib: Was it the molecule or the mechanism?. Arteriosclerosis, Thrombosis, Vasc Biol 2007, 27:257-260.
2. Joy TR, Hegele RA. The failure of torcetrapib: what have we learned?. British J Pharmacol 2008, 154:1379-1381.
3. Zhao L, Jin W, Rader D, Packard C, Feuerstein G. A Translational Medicine perspective of the development of torcetrapib: Does the failure of torcetrapib development cast a shadow on future development of lipid modifying agents, HDL elevation strategies or CETP as a viable molecular target for atherosclerosis? A case study of the use of biomarkers and Translational Medicine in atherosclerosis drug discovery and development. Biochem Pharmacol 2009, 78:315-325.
4. Arrowsmith J. Phase II failures: 2008-2010. Nat Rev Drug Discov 2011, 10:1.
5. Morgan P, Graaf PHVD, Arrowsmith J, Feltner DE, Drummond KS, Wegner CD, Street SDA. Can the flow of medicines be improved? Fundamental pharamacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov Today 2012, 17:419-424.
6. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat Rev Drug Discov 2004, 3:711-715.
7. Arrowsmith J. Phase III and submission failures: 2007-2010. Nat Rev Drug Discov 2011, 10:1.
8. Boucher HW, Talbot GH, Bradley J, JEE G, Bartlett J, Rice LB Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:1-12. Rice LB.
9. Seymour L, Ivy SP, Sargent D, Spriggs D, Baker L, Rubinstein L, Ratain MJ, Blanc ML, Stewart D, Crowley J, Groshen S, Humphrey JS, West P, Berry D. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the National Cancer Institute Investigational Drug Steering Committee. Clin Cancer Res 2010, 16:1764-1769.
10. StopTBPartnership The global plan to stop TB. World Health Organization 2010 [http://www.stoptb.org/assets/documents/global/plan/TB_GlobalPlanToStopTB2011-2015.pdf], StopTBPartnership.
11. Hey SP Meta-heuristic strategies in scientific judgment 2011, University of Western Ontario, Hey SP.
12. Kimmelman J. A theoretical framework for early human studies: Uncertainty, intervention ensembles, and boundaries. Trials 2012, 13:173.
13. Prinz F, Schlange T, Asadullah K. Believe it or not: how much can we rely on published data on potential drug targets?. Nat Rev Drug Discov 2011, 10:712-713.
14. Begley CG, Ellis LM. Raise standards for preclinical cancer research. Nature 2012, 483:531-533.
15. Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J. In Vitro and In Vivo activities of Moxifloxacin and Clinafloxacin against mycobacterium tuberculosis. Antimicrob Agents Chemother 1998, 42:2066-2069.
16. Gillespie S, Billington O. Activity of Moxifloxacin against Mycobacteria. J Antimicrob Chemother 1999, 44:393-395.
17. Shandil RK, Jayaram R, Kaur P, Gaonkar S, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharath S, Balasubramanian V. Moxifloxacin, Ofloxacin, Sparfloxacin, and Ciprofloxacin against Mycobacterium tuberculosis: evaluation of In Vitro and Pharmacodynamic indices that best predict In Vivo efficacy. Antimicrob Agents Chemother 2007, 51:576-582.
18. Miyazaki E, Miyazaki M, Chen J, Chaisson R, Bishai W. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob Agents Chemother 1999, 43:85-89.
19. Lounis N, Bentoucha A, Truffot-Pernot C, Ji B, O'Brien R, Vernon A, Roscigno G, Grosset J. Effectiveness of once-weekly Rifapentine and Moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 2001, 45:3482-3486.
20. Yoshimatsu T, Nuermberger E, Tyagi S, Chaisson R, Bishai W, Grosset J. Bactericidal activity of increasing daily and weekly doses of Moxifloxacin in Murine tuberculosis. Antimicrob Agents Chemother 2002, 46:1875-1879.
21. Nuermberger E, Yoshimatsu T, Tyagi S, O'Brien R, Vernon A, Chaisson R, Bishai W, Grosset J. Moxifloxacin-containing regimen greatly reduces time to culture conversion in Murine tuberculosis. Am J Respir Crit Care Med 2004, 169:421-426.
22. Gosling R, Uiso L, Sam N, Bongard E, Kanduma E, Nyindo M, Morris R, Gillespie S. The bactericidal activity of Moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 2003, 168:1342-1345.
23. Pletz M, Roux AD, Roth A, Neumann K, Mauch H, Lode H. Early bactericidal activity of Moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother 2004, 48:780-782.
24. Gillespie S, Gosling R, Uiso L, Sam N, Kanduma E, McHugh T. Early bactericidal activity of a Moxifloxacin and Isoniazid combination in smear-positive pulmonary tuberculosis. J Antimicrob Chemother 2005, 56:1169-1171.
25. Johnson J, Hadad D, Boom W, Daley C, Peloquin C, Eisenach K, Jankus D, Debanne S, Charlebois E, et al. Maciel E, et al.: Early and extended early bactericidal activity of Levofloxacin, Gatifloxacin and Moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006, 10:605-612.
26. Nijland HMJ, Ruslami R, Suroto AJ, Burger DM, Alisjahbana B, van C, Aarnoutse RE. Rifampicin reduces plasma concentrations of Moxifloxacin in patients with tuberculosis. Clin Infect Dis 2007, 45:1001-1007.
27. Peloquin CA, Hadad DJ, Molino LPD, Palaci M, Boom WH, Dietze R, Johnson JL. Population Pharmacokinetics of Levofloxacin, Gatifloxacin, and Moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 2008, 52:852-857.
28. Burman W, Goldberg S, Muzanye JJG, Engle M, Mosher A, Choudhri S, Daley C, Munsiff S, et al. Zhao Z, et al.: Moxifloxacin versus Ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006, 174:331-338.
29. Rustomjee R, Lienhardt C, Kanyok T, for TB (OFLOTUB) study team G. A phase II study of the sterilising activities of Ofloxacin, Gatifloxacin and Moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008, 12:128-138.
30. Conde M, Efron A, Loredo C, Souza GD, Gracxa N, Cezar M, Ram M, Chaudhary M, Bishai W, Kritski A, Chaisson R. Moxifloxacin versus Ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009, 53:1314-1319.
31. Dorman S, Johnson J, et al. Goldberg S, et al.: Substitution of Moxifloxacin for Isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009, 180:273-280.
32. Wang JY, Wang JT, Tsai T, Hsu C, Yu C, Hsueh P, Lee L, Yang P. Adding Moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis. Int J Tuberc Lung Dis 2009, 14:65-71.
33. Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, Tunis S, Bergel E, Harvey I, Magid DJ, Chalkidou K. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol 2009, 62:464-475.
34. Langan D, Higgins JPT, Gregory W, Sutton AJ. Graphical augmentations to the funnel plot assess the impact of additional evidence on a meta-analysis. J Clin Epidemiol 2012, 65:511-519.